Trial | NCT00369148  Report issue

Title

Combination of Glinides With Premixed Insulin
Evaluation of Usefulness of Combination Therapy of Rapid Acting Insulin Secretagogue (Glinide) With Premixed Insulin in Type 2 Diabetes

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    60
Combination therapy of glinides with premixed insulin provides better glycemic control than premixed insulin alone.
Type 2 diabetic patients undergoing twice daily injections of premixed insulin are administered glinides (10mg of mitiglinide or 90 mg of nateglinide) at lunchtime without changing their insulin regimen. Twelve weeks after administration of the glinides, they are discontinued. HbA1c levels at the start of glinide administration, 12 weeks after administration, and 12 weeks after discontinuation are measured.
Study Started
Jul 31
2004
Study Completion
Mar 31
2006
Last Update
Aug 26
2009
Estimate

Drug nateglinide(drug) mitiglinide(drug)

Criteria 

Inclusion Criteria:

Clinical diagnosis of type 2 diabetes
Who undergoes twice daily injection of premixed insulin
Whose HbA1c is more than 6.5% and less than 8.0%

Exclusion Criteria:

Whose change of HbA1c is more than 1.0% during 12 weeks observational period
No Results Posted